Drug Profile
NRLU 10 PE
Alternative Names: OncoPurgeLatest Information Update: 08 Dec 2003
Price :
$50
*
At a glance
- Originator Poniard Pharmaceuticals
- Class Monoclonal antibodies
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 08 Dec 2003 Discontinued - Phase-II for Cancer in USA (unspecified route)
- 19 Sep 2001 No-Development-Reported for Cancer in USA (Unknown route)
- 17 Oct 1994 Phase-II clinical trials for Cancer in USA (Unknown route)